Kissy is an attorney with more than 20 years of experience, specializing in litigation, business development, and corporate representation. Most recently she served as Associate General Counsel at CryoLife, Inc., and General Counsel of its subsidiary, On-X Life Technologies, Inc., where she supported the Board of Directors and served as lead counsel to its European and Asian business units. She previously founded a cause lawyering firm committed to challenging the Georgia constitutional amendment barring same-sex marriage, litigated at Williams & Connolly LLP in Washington, D.C., and clerked for the Honorable Thomas Penfield Jackson on the Federal District Court for the District of Columbia. Kissy holds a JD from Harvard Law School and a BA from Yale College.
Kissy is an attorney with more than 20 years of experience, specializing in litigation, business development, and corporate representation. Most recently she served as Associate General Counsel at CryoLife, Inc., and General Counsel of its subsidiary, On-X Life Technologies, Inc., where she supported the Board of Directors and served as lead counsel to its European and Asian business units. She previously founded a cause lawyering firm committed to challenging the Georgia constitutional amendment barring same-sex marriage, litigated at Williams & Connolly LLP in Washington, D.C., and clerked for the Honorable Thomas Penfield Jackson on the Federal District Court for the District of Columbia. Kissy holds a JD from Harvard Law School and a BA from Yale College.
Kissy is an attorney with more than 20 years of experience, specializing in litigation, business development, and corporate representation. Most recently she served as Associate General Counsel at CryoLife, Inc., and General Counsel of its subsidiary, On-X Life Technologies, Inc., where she supported the Board of Directors and served as lead counsel to its European and Asian business units. She previously founded a cause lawyering firm committed to challenging the Georgia constitutional amendment barring same-sex marriage, litigated at Williams & Connolly LLP in Washington, D.C., and clerked for the Honorable Thomas Penfield Jackson on the Federal District Court for the District of Columbia. Kissy holds a JD from Harvard Law School and a BA from Yale College.
Jodi is a highly accomplished, results-driven CFO and management executive with more than 30 years of progressive experience in finance and operation management within publicly traded, start-ups, and global organizations. She has demonstrated ability to lead strategic transformation that drives growth, streamlines operations, and increases efficiency and bottom-line profit. Strong qualifications in change management and productivity improvement in addition to developing and implementing financial controls and processes. Jodi possesses solid leadership, communication, and interpersonal skills to establish rapport with all levels of staff and management.
Jodi is a highly accomplished, results-driven CFO and management executive with more than 30 years of progressive experience in finance and operation management within publicly traded, start-ups, and global organizations. She has demonstrated ability to lead strategic transformation that drives growth, streamlines operations, and increases efficiency and bottom-line profit. Strong qualifications in change management and productivity improvement in addition to developing and implementing financial controls and processes. Jodi possesses solid leadership, communication, and interpersonal skills to establish rapport with all levels of staff and management.
Jodi is a highly accomplished, results-driven CFO and management executive with more than 30 years of progressive experience in finance and operation management within publicly traded, start-ups, and global organizations. She has demonstrated ability to lead strategic transformation that drives growth, streamlines operations, and increases efficiency and bottom-line profit. Strong qualifications in change management and productivity improvement in addition to developing and implementing financial controls and processes. Jodi possesses solid leadership, communication, and interpersonal skills to establish rapport with all levels of staff and management.
Kissy is an attorney with more than 20 years of experience, specializing in litigation, business development, and corporate representation. Most recently she served as Associate General Counsel at CryoLife, Inc., and General Counsel of its subsidiary, On-X Life Technologies, Inc., where she supported the Board of Directors and served as lead counsel to its European and Asian business units. She previously founded a cause lawyering firm committed to challenging the Georgia constitutional amendment barring same-sex marriage, litigated at Williams & Connolly LLP in Washington, D.C., and clerked for the Honorable Thomas Penfield Jackson on the Federal District Court for the District of Columbia. Kissy holds a JD from Harvard Law School and a BA from Yale College.
Jodi is a highly accomplished, results-driven CFO and management executive with more than 30 years of progressive experience in finance and operation management within publicly traded, start-ups, and global organizations. She has demonstrated ability to lead strategic transformation that drives growth, streamlines operations, and increases efficiency and bottom-line profit. Strong qualifications in change management and productivity improvement in addition to developing and implementing financial controls and processes. Jodi possesses solid leadership, communication, and interpersonal skills to establish rapport with all levels of staff and management.
Chad leads TwinStrand’s board. He has more than 28 years’ of experience investing in IT and life sciences and serves on the boards of multiple other companies, including NanoString. Chad is the Managing Director of OVP Venture Partners, which has invested in 130 companies, with 53 exits, including 23 IPOs. Notable successes include WatchGuard, Seattle Genetics, and Rosetta Inpharmatics. Prior to joining OVP in 1987, Chad worked in the cardiovascular medical device division of Cobe Laboratories and as a General Partner at H&Q Venture Partners where he invested in IT and life sciences.
Chad leads TwinStrand’s board. He has more than 28 years’ of experience investing in IT and life sciences and serves on the boards of multiple other companies, including NanoString. Chad is the Managing Director of OVP Venture Partners, which has invested in 130 companies, with 53 exits, including 23 IPOs. Notable successes include WatchGuard, Seattle Genetics, and Rosetta Inpharmatics. Prior to joining OVP in 1987, Chad worked in the cardiovascular medical device division of Cobe Laboratories and as a General Partner at H&Q Venture Partners where he invested in IT and life sciences.
Chad leads TwinStrand’s board. He has more than 28 years’ of experience investing in IT and life sciences and serves on the boards of multiple other companies, including NanoString. Chad is the Managing Director of OVP Venture Partners, which has invested in 130 companies, with 53 exits, including 23 IPOs. Notable successes include WatchGuard, Seattle Genetics, and Rosetta Inpharmatics. Prior to joining OVP in 1987, Chad worked in the cardiovascular medical device division of Cobe Laboratories and as a General Partner at H&Q Venture Partners where he invested in IT and life sciences.
David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. David has served on the board or as an observer for a number of companies including Antios Therapeutics and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.
David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. David has served on the board or as an observer for a number of companies including Antios Therapeutics and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.
David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. David has served on the board or as an observer for a number of companies including Antios Therapeutics and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.
Joe is an investor at Madrona focusing on sourcing and evaluating new investment opportunities across Madrona’s investment themes with a focus on the intersection of life and computer sciences. Before joining Madrona, Joe worked in business development at Roche, focusing on accelerating DNA sequencing. Earlier in his career, Joe worked at NanoString commercializing multi-omic technologies and was an associate at the W Fund, investing in early-stage startups in Washington. Joe holds a doctorate in biochemistry from the University of Washington, where he studied the molecular mechanisms underlying the response to H2S.
Joe is an investor at Madrona focusing on sourcing and evaluating new investment opportunities across Madrona’s investment themes with a focus on the intersection of life and computer sciences. Before joining Madrona, Joe worked in business development at Roche, focusing on accelerating DNA sequencing. Earlier in his career, Joe worked at NanoString commercializing multi-omic technologies and was an associate at the W Fund, investing in early-stage startups in Washington. Joe holds a doctorate in biochemistry from the University of Washington, where he studied the molecular mechanisms underlying the response to H2S.
Joe is an investor at Madrona focusing on sourcing and evaluating new investment opportunities across Madrona’s investment themes with a focus on the intersection of life and computer sciences. Before joining Madrona, Joe worked in business development at Roche, focusing on accelerating DNA sequencing. Earlier in his career, Joe worked at NanoString commercializing multi-omic technologies and was an associate at the W Fund, investing in early-stage startups in Washington. Joe holds a doctorate in biochemistry from the University of Washington, where he studied the molecular mechanisms underlying the response to H2S.
Chad leads TwinStrand’s board. He has more than 28 years’ of experience investing in IT and life sciences and serves on the boards of multiple other companies, including NanoString. Chad is the Managing Director of OVP Venture Partners, which has invested in 130 companies, with 53 exits, including 23 IPOs. Notable successes include WatchGuard, Seattle Genetics, and Rosetta Inpharmatics. Prior to joining OVP in 1987, Chad worked in the cardiovascular medical device division of Cobe Laboratories and as a General Partner at H&Q Venture Partners where he invested in IT and life sciences.
David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. David has served on the board or as an observer for a number of companies including Antios Therapeutics and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.
Joe is an investor at Madrona focusing on sourcing and evaluating new investment opportunities across Madrona’s investment themes with a focus on the intersection of life and computer sciences. Before joining Madrona, Joe worked in business development at Roche, focusing on accelerating DNA sequencing. Earlier in his career, Joe worked at NanoString commercializing multi-omic technologies and was an associate at the W Fund, investing in early-stage startups in Washington. Joe holds a doctorate in biochemistry from the University of Washington, where he studied the molecular mechanisms underlying the response to H2S.
Jason has spent his entire career focused on innovations that remove disparity and allow mass adoption of cutting-edge products. At Stanford University School of Medicine, on the heels of the draft of the human genome, he developed several novel functional genomics technologies that were licensed into products. Jason was an early employee at Ion Torrent in 2008 and helped build the first scalable electronic bench-top DNA sequencer ultimately facilitating democratization of genomics. After Ion was acquired by Life Technologies, Jason co-founded ArcherDx and BabyGenes in 2013. Archer merged into Invitae in 2020 to improve access to centralized and decentralized molecular diagnostics across the cancer patient continuum. Over the last 2 years Jason has been exploring electronic biosensors and their capability to offer rapid and inexpensive molecular diagnostics, first as the CEO of Genapsys, and now Sequencing Health. Jason was a board director at Archer, BabyGenes, Invitae, Genapsys, and IsoPlexis. He is currently a director at Sequencing Health and an Independent Director at InterVenn and TwinStrand Biosciences.
Jason has spent his entire career focused on innovations that remove disparity and allow mass adoption of cutting-edge products. At Stanford University School of Medicine, on the heels of the draft of the human genome, he developed several novel functional genomics technologies that were licensed into products. Jason was an early employee at Ion Torrent in 2008 and helped build the first scalable electronic bench-top DNA sequencer ultimately facilitating democratization of genomics. After Ion was acquired by Life Technologies, Jason co-founded ArcherDx and BabyGenes in 2013. Archer merged into Invitae in 2020 to improve access to centralized and decentralized molecular diagnostics across the cancer patient continuum. Over the last 2 years Jason has been exploring electronic biosensors and their capability to offer rapid and inexpensive molecular diagnostics, first as the CEO of Genapsys, and now Sequencing Health. Jason was a board director at Archer, BabyGenes, Invitae, Genapsys, and IsoPlexis. He is currently a director at Sequencing Health and an Independent Director at InterVenn and TwinStrand Biosciences.
Jason has spent his entire career focused on innovations that remove disparity and allow mass adoption of cutting-edge products. At Stanford University School of Medicine, on the heels of the draft of the human genome, he developed several novel functional genomics technologies that were licensed into products. Jason was an early employee at Ion Torrent in 2008 and helped build the first scalable electronic bench-top DNA sequencer ultimately facilitating democratization of genomics. After Ion was acquired by Life Technologies, Jason co-founded ArcherDx and BabyGenes in 2013. Archer merged into Invitae in 2020 to improve access to centralized and decentralized molecular diagnostics across the cancer patient continuum. Over the last 2 years Jason has been exploring electronic biosensors and their capability to offer rapid and inexpensive molecular diagnostics, first as the CEO of Genapsys, and now Sequencing Health. Jason was a board director at Archer, BabyGenes, Invitae, Genapsys, and IsoPlexis. He is currently a director at Sequencing Health and an Independent Director at InterVenn and TwinStrand Biosciences.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then Chairman of Foundation Medicine. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then Chairman of Foundation Medicine. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then Chairman of Foundation Medicine. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
Jason has spent his entire career focused on innovations that remove disparity and allow mass adoption of cutting-edge products. At Stanford University School of Medicine, on the heels of the draft of the human genome, he developed several novel functional genomics technologies that were licensed into products. Jason was an early employee at Ion Torrent in 2008 and helped build the first scalable electronic bench-top DNA sequencer ultimately facilitating democratization of genomics. After Ion was acquired by Life Technologies, Jason co-founded ArcherDx and BabyGenes in 2013. Archer merged into Invitae in 2020 to improve access to centralized and decentralized molecular diagnostics across the cancer patient continuum. Over the last 2 years Jason has been exploring electronic biosensors and their capability to offer rapid and inexpensive molecular diagnostics, first as the CEO of Genapsys, and now Sequencing Health. Jason was a board director at Archer, BabyGenes, Invitae, Genapsys, and IsoPlexis. He is currently a director at Sequencing Health and an Independent Director at InterVenn and TwinStrand Biosciences.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then Chairman of Foundation Medicine. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
For Research Use Only. Not for use in diagnostic procedures.
©2026 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners. Legal Notices